Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
SNYNegative Net Change ANIPPositive Net Change CTMXPositive Net Change ETNBPositive Net Change
biotechs medical pharmaceuticals
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
by Ekta Bagri
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
JNJNegative Net Change ACIUPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
GSKNegative Net Change DVAXPositive Net Change GILDNegative Net Change KRYSPositive Net Change
biotechs
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
RHHBYNegative Net Change NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
by Tirthankar Chakraborty
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
PFENegative Net Change
biotechs medical oncology-screening
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
by Sundeep Ganoria
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
RHHBYNegative Net Change SRPTPositive Net Change PTCTNegative Net Change ARWRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
by Zacks Equity Research
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
NVSNegative Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
by Zacks Equity Research
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
ANIPPositive Net Change CTMXPositive Net Change ETNBPositive Net Change ELEVNegative Net Change
biotechs medical
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
by Zacks Equity Research
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
ALNYPositive Net Change NVSNegative Net Change DVAXPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
DVAXPositive Net Change GILDNegative Net Change OPTNPositive Net Change ARVNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
DVAXPositive Net Change GILDNegative Net Change PCRXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
by Zacks Equity Research
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
DVAXPositive Net Change GILDNegative Net Change ARVNNegative Net Change MIRMNo Net Change
biotechs
GILD Stock Down on Report of Cut in HIV Prevention Spending
by Zacks Equity Research
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
GSKNegative Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.
ENZPositive Net Change
biotechnology biotechs earnings medical
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
by Zacks Equity Research
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
GILDNegative Net Change INCYPositive Net Change SRPTPositive Net Change VTVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
REGNPositive Net Change SNYNegative Net Change NVSNegative Net Change PFENegative Net Change
biotechs medical pharmaceuticals
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
RHHBYNegative Net Change DVAXPositive Net Change GILDNegative Net Change PBYINegative Net Change
biotechs
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
GSKNegative Net Change NVONegative Net Change LLYPositive Net Change HLNNegative Net Change
biotechs
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
DVAXPositive Net Change GILDNegative Net Change ARVNNegative Net Change IMVTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
NVSNegative Net Change RHHBYNegative Net Change DVAXPositive Net Change GILDNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
by Zacks Equity Research
Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'
RHHBYNegative Net Change SRPTPositive Net Change ANIPPositive Net Change CTMXPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
JAZZPositive Net Change AXSMPositive Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
by Zacks Equity Research
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
RDYNo Net Change AMGNNegative Net Change GILDNegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs crispr gene-therapy medical
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
GSKNegative Net Change BMRNPositive Net Change GILDNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals